International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2022 - IJCMAS--ICV 2022: 95.28 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Login as a Reviewer

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 6, Issue:9, September, 2017

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : /
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2017.6(9): 937-944

Role of Bone Sialoprotein-1 and Its Receptor CD44 Variant 6 in Childhood Acute Lymphoblastic Leukemia
Kareman Ahmed Eshra1*, Radwa Mahmoud El- Sharaby2, Mohamed Hossny Fouda2, Dina Adam Elshahat Ali2 and Shaymaa Mohamed Elrifaey3
1Department of Microbiology and Immunology, Tanta University, Egypt
2Department of Clinical pathology, Tanta University, Egypt
3Department of Pediateric and Neonatology, Tanta University, Egypt
*Corresponding author

Acute lymphoblastic leukemia (ALL) represent about 77% of leukemia in children and it is one of the most common malignancies in children. Bone Sialoprotein-1 is a tumor –associated antigen that is highly expressed in many malignancies in human. This study was aimed to study the role of Bone Sialoprotein-1 and its receptors CD44 variant 6 in children’s with acute lymphoblastic Leukemia in Tanta University Hospital. This study was carried out in hematology unit, pediatric department and clinical pathology department, Tanta university hospital, Egypt. 40 children patients were included in this study and 10 healthy controls. The serum levels of Bone Sialoprotein-1 were measured in both healthy control and ALL children patients by ELISA and CD44 variant 6 by flowcytometry. Bone Sialoprotein-1 levels in patient group was 112.69 ± 11.54 ng/mL which was significantly higher than that of control group 8.58 ± 2.19 ng/mL (P value was 0.001), CD44 variant 6 level in patient group was 32.18 ± 15.26 which was significantly higher than that of control group 3.54 ± 1.40 (P value was 0.001) and there was significant difference between level of both Bone Sialoprotein-1 and CD44 variant 6 in cases of good and bad prognosis (P value was0.001). As regard comparison between level of CD44 variant 6 and level of BSP-1 in cases of bad prognosis 22 (55%) of cases were positive for both BSP-1 and CD44 variant 6 and of bad prognosis (P value was 0.002). BSP-1 level and CD44v6 expression in childhood ALL patients may be used as prognostic markers to predict outcome as it has a tendency to be high with cases of bad prognosis.

Keywords: Acute lymphoblastic leukemia, Bone Sialoprotein-1, CD44 variant 6.

Download this article as Download

How to cite this article:

Kareman Ahmed Eshra, Radwa Mahmoud El- Sharaby, Mohamed Hossny Fouda, Dina Adam Elshahat Ali and Shaymaa Mohamed Elrifaey. 2017. Role of Bone Sialoprotein-1 and Its Receptor CD44 Variant 6 in Childhood Acute Lymphoblastic Leukemia.Int.J.Curr.Microbiol.App.Sci. 6(9): 937-944. doi:
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.